Rothschild & Co Redburn Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) Stock

Insulet (NASDAQ:PODD) had its price target hoisted by investment analysts at Rothschild & Co Redburn from $350.00 to $370.00 in a note issued to investors on Friday,MarketScreener reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. Rothschild & Co Redburn’s target price indicates a potential upside of 19.70% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Royal Bank Of Canada increased their price target on Insulet from $330.00 to $350.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Piper Sandler increased their price target on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Wells Fargo & Company increased their price target on Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Citigroup reiterated a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. Finally, Truist Financial started coverage on Insulet in a research report on Monday, June 16th. They set a “buy” rating and a $365.00 price target on the stock. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and a consensus target price of $346.83.

Insulet Trading Down 1.0%

Shares of NASDAQ PODD opened at $309.11 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The stock’s 50 day moving average price is $321.34 and its two-hundred day moving average price is $298.76. The stock has a market capitalization of $21.76 billion, a P/E ratio of 93.95, a PEG ratio of 2.57 and a beta of 1.40. Insulet has a 52-week low of $225.37 and a 52-week high of $353.50.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s quarterly revenue was up 32.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts anticipate that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

Several hedge funds and other institutional investors have recently modified their holdings of the business. Zions Bancorporation National Association UT purchased a new stake in shares of Insulet during the first quarter worth $26,000. Larson Financial Group LLC raised its holdings in Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 81 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 69 shares in the last quarter. SouthState Corp raised its holdings in Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 76 shares in the last quarter. Finally, Kozak & Associates Inc. bought a new position in shares of Insulet in the second quarter worth about $32,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.